Status:
RECRUITING
Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed JIA
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
The Arthritis Society, Canada
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
The PERSON-JIA Trial is a cluster-randomized trial testing the use of Shared Decision Making (SDM) with families for treatment of children with arthritis. The intervention is a discussion between phys...
Detailed Description
The PERSON-JIA (Personalized Estimates of Response and Severity Outcomes in Newly-diagnosed Juvenile Idiopathic Arthritis) trial, will test an innovative shared decision making (SDM) intervention - a ...
Eligibility Criteria
Inclusion
- Physicians (Inclusion):
- Licensed to practice pediatric rheumatology in Canada;
- Providing care for children with JIA at least once a month;
- Consent to be randomized and to implement the SDM intervention for the duration of the trial, if randomized to the intervention arm;
- Commit to propose enrollment in the Registry to all their newly diagnosed patients with JIA during the trial.
- Physicians (Exclusion):
- Fellows-in-training;
- Physicians planning to retire within 2 years.
- Patient (Inclusion):
- Consent to include their information in the CAPRI JIA Registry;
- Consent to the PERSON-JIA trial and answering additional questionnaires to assess decision making;
- Allow recording of their medical encounter (if selected at random);
- JIA fulfilling International League of Associations for Rheumatology (ILAR) criteria;
- Newly diagnosed (within the last month);
- Diagnosed by a pediatric rheumatologist participating in the PERSON-JIA study;
- Not yet receiving treatment, or received only Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or joint injections;
- Patient (Exclusion):
- Systemic arthritis category of JIA (it requires a different treatment approach);
- Family is unable to complete study forms in English or French;
- Patients who have already started systemic corticosteroid or any Disease Modifying Anti-Rheumatic Drug (DMARD).
Exclusion
Key Trial Info
Start Date :
May 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
842 Patients enrolled
Trial Details
Trial ID
NCT05310799
Start Date
May 23 2023
End Date
February 1 2029
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Children's Hospital
Vancouver, British Columbia, Canada, V6H 3N1